Physician
Marque Medical Clinic, INC.
Marque Medical Clinic, INC. was paid $9.48M by Medicaid between Feb 2018 and Dec 2024, across 42 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 50% of everything it billed.
33Billing provider infoMARQUE MEDICAL CLINIC, INC.
NEWPORT BEACH, CA 92660
NEWPORT BEACH, CA 92660
33aNPI1538466107assigned 02/17/2011
33bProvider typeFamily Medicine Physician
28Total paid$9.48M
24GClaims160,468
24DCodes billed42
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#44 of 2,511
Median peer was paid$13K
This provider vs. median738×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,762 | $580K | |
| 2019 | 8,335 | $533K | |
| 2020 | 8,781 | $609K | |
| 2021 | 14,652 | $1.01M | |
| 2022 | 27,090 | $1.73M | |
| 2023 | 47,082 | $2.68M | |
| 2024incomplete | 45,766 | $2.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 50% | 70,327 | 63,402 | $4.71M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 35% | 43,491 | 43,155 | $3.28M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.2% | 7,422 | 7,063 | $496K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.1% | 4,123 | 4,093 | $297K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.1% | 5,797 | 5,625 | $195K |
| 99070 | 1.7% | 4,754 | 3,909 | $158K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 1,502 | 1,422 | $121K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 909 | 822 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,077 | 1,995 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,844 | 2,935 | $27K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,810 | 4,745 | $18K |
| 0002A | <1% | 178 | 178 | $7K |
30 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 203 | $5K |
| 0001A | <1% | 138 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 262 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 43 | $4K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 44 | $4K |
| 0004A | <1% | 89 | $4K | |
| 0012A | <1% | 76 | $3K | |
| 0064A | <1% | 74 | $3K | |
| 81025 | <1% | 1,288 | $2K | |
| 0011A | <1% | 55 | $2K | |
| 81003 | <1% | 2,590 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 15 | $2K |
| 81002 | <1% | 1,115 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $1K |
| 99072 | <1% | 983 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 203 | $1K |
| 99000 | <1% | 1,414 | $957.72 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 179 | $872.73 |
| 73630 | <1% | 40 | $722.88 | |
| 73610 | <1% | 41 | $677.40 | |
| 0003A | <1% | 12 | $480.00 | |
| 69209 | <1% | 27 | $178.56 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 13 | $144.49 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 26 | $106.37 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16 | $81.56 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 20 | $51.31 |
| A4927 | Gloves, non-sterile, per 100 | <1% | 205 | $16.84 |
| A6413 | Adhesive bandage, first-aid type, any size, each | <1% | 24 | $12.00 |
| A5120 | Skin barrier, wipes or swabs, each | <1% | 12 | $1.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 13 | $0.75 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKISKILA, NATHAN (PRESIDENT)